D. Western Therapeutics Institute Inc 4576
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 110.00
- Day Range
- JPY 105.00–111.00
- 52-Week Range
- JPY 105.00–238.00
- Bid/Ask
- JPY 106.00 / JPY 107.00
- Market Cap
- JPY 3.44 Bil
- Volume/Avg
- 234,300 / 93,991
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- http://www.dwti.co.jp
Comparables
Valuation
Metric
|
4576
|
4563
|
2929
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 5.09 |
Price/Book Value | 2.76 | 0.39 | 2.56 |
Price/Sales | 8.16 | 63.11 | 0.37 |
Price/Cash Flow | — | — | 4.12 |
Price/Earnings
4576
4563
2929
Financial Strength
Metric
|
4576
|
4563
|
2929
|
---|---|---|---|
Quick Ratio | 10.23 | 1.68 | 0.80 |
Current Ratio | 11.02 | 2.38 | 1.07 |
Interest Coverage | −331.05 | — | 116.29 |
Quick Ratio
4576
4563
2929
Profitability
Metric
|
4576
|
4563
|
2929
|
---|---|---|---|
Return on Assets (Normalized) | −29.22% | −16.00% | 16.62% |
Return on Equity (Normalized) | −46.93% | −19.90% | 71.66% |
Return on Invested Capital (Normalized) | −30.81% | −19.26% | 21.06% |
Return on Assets
4576
4563
2929
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hwfqmcrdz | Rmnt | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bjvspqlg | Cyhnhw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gbvvpjflj | Kkfsgpr | $98.1 Bil | |
MRNA
| Moderna Inc | Qglfbnj | Pzmcn | $39.1 Bil | |
ARGX
| argenx SE ADR | Fvbfwczt | Jxym | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Brxkzvshs | Nvlvr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kkfvhfzk | Mqyqhj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rljhkqky | Vhkxh | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xlxlhtllz | Nmbqfrv | $12.5 Bil | |
INCY
| Incyte Corp | Qjkbqfyxm | Qxjcsg | $11.9 Bil |